The inhibition of mToR by Everolimus also results in a complex favorable modulation of cancer and of immune response interplay (Hernández et al., 2011; Fasolo and Sessa, 2014; Sabbatini et al., 2015; Johnson et al., 2018). The gene discussed is MTOR; the disease is cancer.